Venture Capital/News/ Asabys Partners announces €100m first close for health and biotech fund It’ll look to back around 12-15 startups in the UK, Europe, Israel and the US By Kai Nicol-Schwarz 15 February 2023 Asabys Partners Asabys Partners \Venture Capital Speedinvest starts €3m fund of funds programme to back emerging managers By Eleanor Warnock 17 February 2023 Venture Capital/News/ Asabys Partners announces €100m first close for health and biotech fund It’ll look to back around 12-15 startups in the UK, Europe, Israel and the US By Kai Nicol-Schwarz 15 February 2023 Barcelona-based health and life science-focused VC Asabys Partners is announcing a €100m first close of its second fund. It’s targeting a total of €200m — which it hopes to hit later this year — and will look to invest in startups with scientifically proven medical solutions. The first close came a couple of months later than the VC predicted when it announced it was raising for its second fund back in September — which could be a sign of the tricky fundraising landscape VCs are faced with at present. Where will the money be spent? Asabys Partners will invest €2m-5m in 12-15 startups in the UK, Europe, Israel and the US. The firm says it will invest up to €15m in follow-on rounds. Associate Maite Malet says the firm is particularly interested in investing in startups working on solutions in diagnostics and therapeutics segments like: Women’s health Neurology Chronic diseases Oncology Cardiology Immunology Where’s the money coming from? As with Asabys Partners’ first fund — which it raised in 2018 — Spanish banking group Banco Sabadell is the main private institutional investor. Other investors include the European Investment Fund — which recently announced a €3.75bn scaleup fund of funds — and Alantra. Asabys’s portfolio Asabys Partners was founded by Josep Sanfeliu — one of Spain’s most active angel investors in 2021 — and Clara Campàs. Since launching, the VC has backed 13 companies in the biopharma, medtech and digital health sectors and has around €217m assets-under-management, according to the firm. They include: Berlin-based gut health platform Cara Care, which raised $7m in June 2022. Iceland’s digital therapeutics startup Sidekick Health, which raised a $55m Series B in May 2022. Spanish startup Ona Therapeutics, which is developing novel therapies for metastatic cancer and raised €30m in June 2020. AgomAb Therapeutics, which is developing treatment to repair organ and tissue damage, raised a $40.5m Series B participated in by Pfizer. Kai Nicol-Schwarz is a reporter at Sifted. He tweets from @NicolSchwarzK. Related Articles Remember the Future Fund? Here’s where the UK government’s money went By Amy Lewin Click here to read more Latitude: LocalGlobe’s ‘breakout’ fund breaks cover By Amy Lewin Click here to read more Six startup ideas — from Germany’s top VCs By Miriam Partington in Berlin Click here to read more Snoop Dogg’s VC makes first investment in continental Europe By Tim Smith Click here to read more Most Read 1 \Healthtech Is Daniel Ek’s new body scanner worth the hype? Sifted tried it out 2 \Venture Capital VC diversity needs to change — and white men need to take responsibility 3 \Venture Capital New €3.75bn European Investment Fund pot to back late-stage VCs 4 \Sustainability Counteract closes £15m fund for carbon removal solutions 5 \Mobility Was the $5bn that VCs plugged into escooters worth it?
Remember the Future Fund? Here’s where the UK government’s money went By Amy Lewin Click here to read more